May 9, 2019
Takeda sells Xiidra to Novartis for up to $5.3B, TachoSil to Ethicon for $400M
Takeda sells Xiidra to Novartis for up to$5.3 billion, TachoSil to Ethicon for approximately $400 million
Pharmaceuticals, Biotechnology and Life Sciences
Takeda sells Xiidra to Novartis for up to$5.3 billion, TachoSil to Ethicon for approximately $400 million